News Summaries

China’s Stem Cell Boom: New Policies, Breakthrough Therapies, and Global Partnerships Unveiled at Zhangjiang Conference

The Zhangjiang Pharmaceutical Valley International Innovation Conference gathered top scientists, regulators, and industry leaders to map the future of stem‑cell medicine in China. Academician Li Xiaokun opened the event with a roadmap for turning cell‑growth‑factor research into real drugs, while Wu Zhaohui explained how the newly issued “Order 818” will shift cell‑therapy from a gray‑area research field to a fully regulated industry. Tang Minhao broke down the latest revisions to the Drug Administration Law, giving clear guidance for stem‑cell drug approvals. Key scientific highlights included Chen Xiangmei’s review of global and Chinese advances in stem‑cell treatment for chronic kidney disease, and Xu Huji’s outlook on universal CAR‑T cells for autoimmune disorders. Academics Li Jinsong and Wang Fusheng showcased semi‑cloning technology and cell‑therapy strategies for liver and infectious diseases, while Gao Shaorong painted a vision of pluripotent stem cells leading regenerative medicine. International voices—French technologist Han Zhongchao and Russian engineer Zhang Dan—discussed the business impact of Orders 818/828 and the rise of exosome‑based anti‑aging products. Industry sessions offered practical roadmaps for moving discoveries from the lab to market, covering everything from biosample data platforms to universal organ‑transplant strategies. The conference underscored China’s rapid shift from catching up to setting the global agenda in stem‑cell innovation, driven by supportive policy, cutting‑edge research, and a growing investment ecosystem.

China’s Doctors Lead the Charge in Cutting‑Edge Cancer Drug Trials

Chinese pharmaceutical research is moving beyond simply copying foreign drugs (“me‑too”) to creating superior and breakthrough therapies (“me‑better” and “me‑best”). Thanks to a massive patient pool and relentless work ethic, Chinese clinicians are now enrolling patients at a speed that would take years in the West. For example, Dr. Qiu Haibo’s Phase III study on SDH‑deficient gastrointestinal stromal tumors recruited all 51 participants in just one year, a timeline that would normally stretch two to three years in Europe or the U.S. Doctors like Qiu and Dr. Shi Yuankai work around the clock—performing surgeries, consulting patients, and flying to international conferences with barely a break. Their dedication is matched by patients who readily join trials, allowing China to fast‑track approvals and set new standards of care. At the ASCO meeting, Chinese teams presented advances in bispecific antibodies, ADCs, trispecific antibodies and CAR‑T therapies, signaling global leadership in niche oncology fields. While China now excels in late‑stage development, experts acknowledge gaps in early‑stage (“0‑1”) research and clinical quality. International collaborations are growing, with foreign biotech firms increasingly trusting Chinese data and seeking to run trials in China. The evolution—from proving drugs are “no worse” than imports to showing they are truly better—marks a new era for Chinese medicine, benefitting patients worldwide.